ECAR-01

N/A

Report date: 2025/07/16 17:08:36

Base Information

Drug NameECAR-01
Drug Alias NameAutologous CAR-T Cell Injection (ECAR01) Targeting BCMA and CD19 therapy (Anhui Provincial Hospital)ECAR-01ECAR01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19Anti-BCMAT lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesAnhui Provincial Hospital
China Registration ClassN/A

Develop Information

Active CompaniesAnhui Provincial Hospital
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A